home / stock / immx / immx news


IMMX News and Press, Immix Biopharma Inc. From 06/20/23

Stock Information

Company Name: Immix Biopharma Inc.
Stock Symbol: IMMX
Market: NASDAQ
Website: immixbio.com

Menu

IMMX IMMX Quote IMMX Short IMMX News IMMX Articles IMMX Message Board
Get IMMX Alerts

News, Short Squeeze, Breakout and More Instantly...

IMMX - Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors

Mr. Cooper joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical industry, including 5 years as Chief Financial Officer of BioMarin Pharmaceutical Mr. Cooper is a former independent director of Sierra Oncology, acquired by GlaxoSmithKline for ...

IMMX - Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors

Dr. Coleman joins the Nexcella, Inc. Board of Directors with over a decade of experience as an Independent Director of Johnson & Johnson from 2003-2016 Dr. Coleman is President Emerita of the University of Michigan where she was named one of “10 Best College Presidents” by T...

IMMX - Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program

LOS ANGELES, June 14, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc., (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering CAR-T cell therapies and tissue specific therapeutics targeting oncology and im...

IMMX - Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors

Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive Officer Dr. McKinnell is a former independent director of ChemoCentryx, acquired by Amgen for $3.7 billion in 2022 and former Chairman/CEO o...

IMMX - HeartBeam, Taro top healthcare gainers; Enveric, Bright Health among losers

2023-05-30 10:01:01 ET Gainers: HeartBeam ( BEAT ) +23% . Taro Pharmaceutical Industries ( TARO ) +22% . Akebia Therapeutics ( AKBA ) +19% . Corvus Pharmaceuticals ( CRVS ) +16% . Immix Biopharma ( IMMX ) +13% . Losers:...

IMMX - RIOT, AI and IOVA are among pre market gainers

2023-05-30 08:34:33 ET Arlington Asset Investment  ( AAIC ) +53% Announce Definitive Merger Agreement. Equitrans Midstream  ( ETRN ) +33% . HeartBeam ( BEAT ) +28% Enters into Strategic Alliance Agreement with Samsung. Wearable Devices  (...

IMMX - Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site

U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering batches are the first step in transferring the Company’s existing CAR-T GMP manufacturing process to the United States Commenceme...

IMMX - TIO, IMMX and CDIO among pre-market losers

2023-05-26 08:31:34 ET SunCar Technology Group ( SDA ) -27% . Wearable Devices ( WLDS ) -26% . Tilray Brands ( TLRY ) -22% follows $150M convertible note offering . Nano Labs ( NA ) -16% . Beamr Imaging ( BMR ) -15% . HEXO ( ...

IMMX - ARVL, MNK and MVST are among pre market losers

2023-05-23 08:45:00 ET Biocept ( BIOC ) 10% . Microvast Holdings ( MVST ) -20% plunges as Energy Department said to cancel DoE contract. Wave Life Sciences  ( WVE ) -13% crashes on decision to drop neurology asset on trial setback. ToughBuilt I...

IMMX - Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10 -5 ) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS 62% (5/8) had NYHA classificat...

Previous 10 Next 10